Thomas Lingelbach, Valneva CEO

A small vac­cine de­vel­op­er fa­vored by the UK gov­ern­ment in Covid-19 touts a PhI­II first in chikun­gun­ya

Be­fore Val­ne­va gar­nered the fa­vor of the UK gov­ern­ment as a po­ten­tial sup­pli­er of Covid-19 vac­cines, the French biotech prid­ed it­self on be­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.